Screening molecular markers in early breast cancer of the same pathological types but with different prognoses using Agilent gene chip
- VernacularTitle:利用Agilent定制基因芯片筛选相同病理类型、不同预后的早期乳腺癌的分子标记物
- Author:
Zhou LI
1
;
Liang PENG
;
Shuai HAN
;
Zonghai HUANG
;
Fujun SHI
;
Zhai CAI
;
Xiuqin LI
;
Pusheng ZHANG
;
Huijuan ZHU
;
Weirong JIN
Author Information
1. 南方医科大学珠江医院普外科
- Keywords:
breast tumors;
genes;
chip analysis techniques;
molecular typing
- From:
Journal of Southern Medical University
2013;(10):1483-1488
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To screen molecular markers in early breast cancer and establish gene subtyping-based diagnostic criteria for predicting the prognosis of early breast cancers. Methods Tumor tissue specimens were obtained from 8 patients with early breast cancer for analysis of the differentially expressed genes using Agilent custom 8 × 15 000 chips in combination with the prognostic data of the patients. Another 42 tumor tissue specimens were used to validate the differential genes by real-time fluorescent quantitative PCR. Results Gene microarray analysis identified 132 differentially expressed genes between the patients with favorable and poor prognosis, and 44 of these genes were significantly up-regulated (by over two folds) and 88 down-regulated in patients with poor prognoses. Conclusion The gene expression profiles differ in early breast cancer tissues of the same pathological type but with different clinical stages and prognoses, and CD44, MKI67, NTRK2, Nek2, C16orf60, TOP2A, ANCCA, and RRM2 genes can be used as the prognostic markers for early breast cancer.
